RLMD - יחס חוב להיוון בספרים Relmada Therapeutics Inc

Relmada Therapeutics (RLMD) relies on global partnerships for the study of neuropathologies, which are currently complicated by geopolitics and sanctions. This GURU.Markets chart of the total debt-to-equity ratio illustrates the financing structure, where the 0.00 mark reflects the latest data. High R&D expenditures and strict FDA oversight create barriers, while the reliance on a single drug increases business risks.

This indicator determines the financial resilience of Relmada Therapeutics (RLMD) to market shocks. The development of NMDA receptor antagonists for the treatment of resistant depression requires significant capital expenditures. The debt-to-equity ratio reflects the proportion of liabilities relative to equity in a real-time assessment. This metric allows for an evaluation of bankruptcy risk and the company's degree of leverage. While a low debt level confirms reliability, excessive conservatism may slow expansion within the mental health market.